Marksans Pharma Gets UK MHRA Nod for Exemestane Tablets

Marksans Pharma Limited has announced that its wholly owned subsidiary in the United Kingdom, Relonchem Limited, has obtained Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its product Exemestane 25mg film-coated tablets.

Exemestane is a crucial therapeutic agent utilized in the treatment of specific types of breast cancer in postmenopausal women. This approval enhances Marksans Pharma’s oncology portfolio and underscores its dedication to expanding its footprint in regulated markets with high-quality, affordable medications. In response to the approval, Mark Saldanha, Managing Director of Marksans Pharma Limited, stated, “This authorization from the UK MHRA signifies another significant milestone in our growth journey. It demonstrates our ongoing commitment to developing and delivering high-quality pharmaceutical products that address critical patient needs across global markets.”

Also Read: New Advanced Heart Failure Clinic Launched at Medicity

With this approval, Relonchem Limited is set to further enrich its product offerings in the UK, thereby reinforcing Marksans Pharma’s status as a reliable global healthcare provider. Marksans Pharma Limited is an Indian pharmaceutical company based in Mumbai, founded in 1992. The company specializes in the research, manufacturing, and marketing of generic pharmaceutical formulations for both prescription and over-the-counter markets. Its product range spans various therapeutic areas, including cardiovascular, central nervous system, anti-diabetic, pain management, gastroenterology, and respiratory care.

Marksans Pharma operates on a global scale in over 50 countries, with manufacturing facilities situated in India, the United Kingdom, and the United States. These facilities are accredited by prominent regulatory bodies such as the US FDA, UK MHRA, and Australian TGA. The company’s shares are traded on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) under the ticker symbol “MARKSANS.”